Background: Phosphodiesterase type 4 (PDE4) inhibitors produce widespread anti-inflammatory effects and reduce ethanol (EtOH) consumption in several rodent models. These drugs are potential treatments for several diseases, including central nervous system disorders, but clinical use is limited by their emetic activity. Apremilast is a selective PDE4 inhibitor with fewer gastrointestinal side effects that is FDA-approved for the treatment of psoriasis.
A LCOHOL MISUSE PLACES a tremendous economic burden on our society (estimated cost of $249 billion/y in the United States in 2010) and is a leading risk factor for premature death and disability worldwide (niaaa.nih.gov/alc ohol-health/overview-alcohol-consumption/alcohol-facts-andstatistics). Disulfiram, naltrexone, and acamprosate are the only FDA-approved drugs to treat alcohol use disorder (AUD). These drugs have limited clinical efficacy and are not routinely prescribed, and thus, there is a critical need for improved treatment options. Behavioral and genetic evidence supports roles for immune/inflammatory signaling in alcohol abuse, including neuroimmune pathways (Crews and Vetreno, 2016; Mayfield et al., 2013; Montesinos et al., 2016; Warden et al., 2016) . This area of research shows great potential to advance treatment strategies for AUD.
Phosphodiesterases (PDEs) regulate immune pathways, and PDE4 in particular has been implicated in alcohol and substance use disorders. PDEs are a superfamily of enzymes catalyzing the hydrolysis of 3 0 ,5 0 -cyclic adenosine monophosphate (cAMP) and 3 0 ,5 0 -cyclic guanosine monophosphate (cGMP) to their inactive 5 0 -AMP and 5 0 -GMP forms, respectively. Increased cAMP or cGMP, resulting from inhibition of PDE, reduces inflammatory signaling on a broad scale (Jin et al., 2012; Page and Spina, 2011) . Cyclic nucleotides play pivotal roles in many cellular processes, including immune/inflammatory responses, cardiac function, smooth muscle relaxation, depression, and cognition. The anti-inflammatory actions of PDE inhibitors are beneficial in treating chronic obstructive pulmonary disease and asthma (Jin et al., 2012; Keravis and Lugnier, 2012) . PDEs are encoded by 21 genes and are grouped into 11 families, according to their structural similarity. Each gene encodes multiple protein products generated by different promoters and alternative splicing events, resulting in more than 50 different PDE proteins that may be produced in mammalian cells (Bender and Beavo, 2006) .
Our study of different classes of PDE inhibitors showed that only PDE4 inhibitors decreased ethanol (EtOH) drinking in mice (Blednov et al., 2014) . The PDE4 inhibitor rolipram markedly reduced EtOH intake and preference in mice (Hu et al., 2011) and reduced EtOH seeking and consumption in alcohol-preferring fawn-hooded rats (Wen et al., 2012) . In addition, rolipram diminished anxiety-and depression-like behaviors induced by abstinence from EtOH in different rodent models (Gong et al., 2017) and inhibited neuroimmune signaling in preclinical and clinical models (Zhu et al., 2001) . The nonselective PDE inhibitor ibudilast (Gibson et al., 2006 ) also reduced EtOH consumption in 3 different rodent models (Bell et al., 2015) . It did not alter primary measures of subjective responses to alcohol in a human laboratory trial but improved cue-and stressinduced changes in mood and decreased craving (Ray et al., 2017) . Ibudilast did decrease the reward-related subjective effects of methamphetamine in dependent individuals (Worley et al., 2016) and decreased the subjective effects of oxycodone and drug cravings in opioid-dependent individuals who had undergone detoxification (Metz et al., 2017) . In addition to drug addiction, PDE4 inhibitors have been investigated as potential therapeutics in diverse central nervous system (CNS) disorders such as depression, anxiety, schizophrenia, Parkinson's disease, and Alzheimer's disease (Halene and Siegel, 2007; Kanes et al., 2007; Smith et al., 2009) .
Considering the widespread anti-inflammatory effects of PDE4 inhibitors and their ability to substantially reduce drinking in rodent models, they are strong candidates for treating AUD and other inflammatory disorders. However, improved prototypes with fewer side effects in humans are needed. We tested apremilast, a novel PDE4 inhibitor with diminished emetic activity that is currently used to treat psoriasis. Drug repurposing is an expedient and cost-efficient means of drug discovery, and prioritizing study of FDA-approved drugs to treat AUD is especially important considering the limited number of options available. We also note that it has been more than a decade since the latest drug for AUD was approved. In this study, we used 2 tests that can produce different levels of EtOH intake in mice and that model different patterns of drinking in humans. Continuous 2-bottle choice (2BC) drinking is the most widely used test of voluntary EtOH consumption and is associated with other measures of EtOH reward, while the 2BC intermittent (every other day [EOD] ) test can increase EtOH consumption in C57BL/6J mice (Melendez, 2011) . Apremilast significantly reduced EtOH intake in both the 2BC and 2BC-EOD drinking tests in male and female C57BL/6J mice.
MATERIALS AND METHODS

Mice
C57BL/6J male and female mice were from a colony maintained at The University of Texas at Austin (original breeders were purchased from The Jackson Laboratory, Bar Harbor, ME). Mice were group-housed 4 or 5 to a cage, and food and water were available ad libitum. The vivarium was maintained on a 12-hour light/dark cycle with lights on at 7:00 AM; however, for studies of EtOH and saccharin/sucrose intake, mice were housed on a reverse light cycle schedule. The temperature and humidity of the rooms were kept constant. Behavioral testing began when the mice were 2 to 3 months old. Experiments were conducted in isolated behavioral testing rooms in the Animal Resources Center at The University of Texas at Austin, and mice were allowed to adapt to the rooms for 1 week before testing began. Separate groups of mice were used for the different drinking and behavioral tests used in this study and that of our companion study (Blednov et al., 2018) , with the exception of locomotor activity testing in which the same group of mice are represented in both studies. Experiments were approved by the university's Institutional Animal Care and Use Committee.
Apremilast Administration
Apremilast was purchased from Toronto Research Chemicals Inc. (Toronto, ON, Canada), freshly prepared as a suspension in saline with 3 to 4 drops of Tween 80, and administered daily in a volume of 0.05 ml/10 g of body weight, 1 hour before the experiments. Control mice received the same injection volume of saline containing 3 to 4 drops of Tween 80. Single use, sterile gavage needles (27.5 gauge; Becton, Dickinson and Co., Franklin Lakes, NJ) were used. For chronic drug studies, saline or apremilast (20 mg/kg, p.o.) was administered daily for 6 to 11 days, depending on the drinking test. Drinking was then measured in the absence of apremilast for 2 or 4 days after saline injection. Apremilast doses were based on our initial dose-response studies.
Baseline EtOH Drinking
Mice undergoing 2BC testing first consumed 15% (v/v) EtOH (Sigma-Aldrich, St. Louis, MO) for about 3 weeks, while baseline drinking in the 2BC-EOD group lasted about 5 weeks to provide a similar number of EtOH-drinking sessions in each group before beginning the experiments. After these initial access periods, EtOH consumption was measured for at least 4 days to ensure stable levels of consumption (i.e., <10% variation in average intake on days 1 to 2 and days 3 to 4). EtOH intake was then measured after saline injection for 2 days, and mice were assigned to treatment and control groups based on similar levels of EtOH intake and preference. EtOH intake and total fluid intake are shown as g/kg body weight/ 24 h averaged for 2 drinking days. On drinking day 3, mice were injected once daily with either saline or apremilast for 6 to 11 days, depending on the drinking test. For dose-response measurements, saline or apremilast was injected daily for 2 days in the continuous 2BC test and for 3 days in the 2BC-EOD test.
Continuous 2BC EtOH Drinking
The 24-hour 2BC protocol, in which each mouse had access to a bottle of water and a bottle of EtOH, was carried out as previously described (Blednov et al., 2001) . Bottles were weighed daily, and positions were alternated daily to control for side preferences. Food was available ad libitum, and mice were weighed every 4 days. Consumption of 15% (v/v) EtOH and water (g/kg/ 24 h) was calculated for each mouse. Measurements of EtOH intake, preference, and total fluid intake were averaged over 2 drinking days with different bottle positions. Each point in the line graphs represents the average of 2 days of measurement. For example, day 2 is the average of days 1 to 2 and day 4 is the average of days 3 to 4.
Intermittent 2BC EtOH Drinking
Intermittent access to EtOH induces high voluntary consumption in rats (Simms et al., 2008) and mice (Rosenwasser et al., 2013) . We used this method to measure EtOH intake in mice with access to a bottle of 15% (v/v) EtOH and a bottle of water during 24-hour drinking sessions offered every other day. The placement of the EtOH bottle was alternated with each drinking session to control for side preferences. Food was available ad libitum, and mice were weighed every 4 days. Consumption of 15% EtOH and water (g/ kg/24 h) was calculated for each mouse. Measurements of EtOH intake, preference, and total fluid intake were averaged over 2 drinking days with different bottle positions.
Saccharin, Sucrose, and Water Intake Saccharin (0.0165%, Sigma-Aldrich) and sucrose (1%, SigmaAldrich) intake experiments were carried out using the 2BC procedure. For both sweeteners, stable basal levels of consumption were established followed by 2 days of control measurements when all mice received saline 1 hour before the drinking session. Then saline or apremilast injections continued for 6 to 8 days. Water intake was measured using 1 bottle of water.
Locomotor Activity
Locomotor activity was measured in standard mouse cages using the Opto-microvarimex animal activity meter (Columbus Instruments, Columbus, OH). Activity was monitored by 6 light beams spaced along the width of the cage at 2.5-cm intervals, 1.5 cm above the floor. Each cage had bedding and food and was covered by a heavy plastic lid with holes for ventilation. On the day of the experiment, mice were placed in individual experimental cages, and activity was monitored hourly for 22 hours. Saline or apremilast (20 mg/ kg) was administered 1 hour before locomotor activity was monitored. For chronic drug treatment, apremilast (20 mg/kg) was administered daily for 6 days, and locomotor activity was measured on day 6, 1 hour after the last drug injection.
Blood EtOH Concentration
The effect of saline or apremilast (20 mg/kg) on blood EtOH concentration (BEC) was measured over the course of 4 hours after injection of EtOH (4 g/kg, i.p.). Retro-orbital blood samples (~20 ll) were collected in capillary tubes and centrifuged for 6 minutes at 3,1009g using a Haematospin 1400 centrifuge (Analox Instruments, London, UK). Plasma samples were stored at À20°C until BECs were determined in 5-ll aliquots using an AM1 Alcohol Analyzer (Analox Instruments). The machine was calibrated every 15 samples using an industry standard, and BECs were determined using commercially available reagents according to the manufacturer's instructions. Samples were averaged from duplicate runs and expressed as mg/dl. Fig. 1 . Apremilast dose dependently decreases 15% ethanol (EtOH) intake in the continuous 2BC test. Effects of apremilast (5 to 50 mg/kg) on EtOH intake (A), preference for EtOH (B), and total fluid intake (C) in male C57BL/6J mice; n = 7 to 8 per group. Effects of apremilast (5 to 50 mg/kg) on EtOH intake (D), preference for EtOH (E), and total fluid intake (F) in female C57BL/6J mice; n = 6 to 7 per group. Data are presented as the differences between 2-day drinking averages after drug injection (days 3, 4 after apremilast) and the first 2 days of saline (control) injections (days 1, 2). Data were analyzed by 1-way ANOVA with Bonferroni post hoc tests (*p < 0.05, **p < 0.01, ***p < 0.001 compared with control).
Biodistribution of Apremilast
Plasma, liver, and brain samples from male C57BL/6J mice were collected 1 or 2 hours after a single oral dose of apremilast (20 mg/kg). Plasma and tissue apremilast concentrations were measured using salting-out assisted liquid-liquid extraction and reversedphase high-performance liquid chromatography (HPLC) with UV detection. Apremilast and the internal standard naproxen (MP Biomedicals, Santa Ana, CA) were quantitatively extracted from 100 ll of plasma, 1 hemisphere of brain (210 to 286 mg), or 200 AE 15 mg of liver tissue. Plasma samples were thawed; 20 ll of internal standard, 20 ll of 20 mM citric acid (Thermo Fisher Scientific, Waltham, MA), and 500 ll of acetonitrile; Thermo Fisher Scientific) were added, with 30 seconds of vortex-mixing, followed by the addition of 100 ll of 5 M magnesium chloride (Thermo Fisher Scientific) and 1 minute of vortex-mixing. This mixture was centrifuged at 16,9009g for 5 minutes, and then, the upper layer (acetonitrile) was transferred into an HPLC vial and evaporated under a stream of nitrogen at~30°C. The residue was reconstituted in 50 ll of (60:40) acetonitrile/10 mM citric acid solution (v/v), and 5 ll were injected into the HPLC for analysis.
Brain and liver samples were thawed, and a total of 50 ll of internal standard, 50 ll of 20 mM citric acid, and 400 ll of acetonitrile were added with 30 seconds of vortex-mixing, followed by centrifugation at 16,9009g for 1 minute. Tissue was homogenized (ProScientific 200 homogenizer; Pro Scientific, Oxford, CT) for 1 minute. An additional 750-ll aliquot of acetonitrile was added to the homogenate, and the sample was vortex-mixed for 30 seconds, followed by the addition of 300 ll of a mixture of 5 M sodium chloride (BDH Chemicals, West Chester, PA) and 2.5 M ammonium sulfate (Thermo Fisher Scientific), and 1 minute of vortex-mixing. This mixture was centrifuged at 16,9009g for 15 minutes. For brain tissue, 1 ml of the upper layer (acetonitrile) was filtered through 0.2 lm polytetrafluoroethylene (Corning Inc., Corning, NY) into an HPLC vial and evaporated under a stream of nitrogen at~30°C. The residue was reconstituted in 50 ll of acetonitrile, and 5 ll were injected into the HPLC for analysis. For liver tissue, 1 ml of the upper layer (acetonitrile) was transferred to a centrifuge tube, and then, 300 ll of 5 M magnesium chloride was added, followed by 1 minute of vortex-mixing. This mixture was centrifuged at 16,9009g for 15 minutes, and 900 ll of the upper layer (acetonitrile) was filtered through 0.2 lm polytetrafluoroethylene into an HPLC vial and evaporated under a stream of nitrogen at~30°C. The residue was reconstituted in 50 ll of acetonitrile, and 5 ll were injected into the HPLC as described below.
Calibration curves were prepared by spiking apremilast into blank mouse plasma (0.01 to 10 lg/ml), brain (0.025 to 1.25 lg/ml), and liver tissue (0.06 to 125 lg/ml), in triplicate across a minimum of 6 levels of apremilast. Method selectivity was verified by extracting and analyzing unspiked blank samples. The chromatographic Fig. 2 . Apremilast produces stable reduction of 15% ethanol (EtOH) intake in the continuous 2BC test. Effects of apremilast (20 mg/kg) on EtOH intake (A), preference for EtOH (B), and total fluid intake (C) in male C57BL/6J mice; n = 8 per group. Effects of apremilast (20 mg/kg) on EtOH intake (D), preference for EtOH (E), and total fluid intake (F) in female C57BL/6J mice; n = 9 per group. Each data point represents the average of 2 days of drinking. S/S represents 2-day drinking averages after saline injections for both groups. S/Drug represents the 2-day averages after saline or apremilast injections (6 days total). The second S/S period shows the extinction (2 to 4 days total) of effects on drinking in mice previously treated with apremilast. Data were analyzed by 2-way repeated measures ANOVA.
assay was performed with a Dionex Ultimate 3000 HPLC with UV detector (Dionex Corp., Sunnyvale, CA) using gradient elution on an Eclipse Plus C18 column (3.0 9 150 mm, 3.5 lm) with an EC-18 guard column (3.0 9 5.0 mm, 2.7 lm; Agilent Technologies, Santa Clara, CA), 30°C column temperature, 230 nm, and a run time of 15 minutes. A ternary gradient separation was performed using 0.1% phosphoric acid (EMD Chemicals, Gibbstown, NJ) in water (v/v), acetonitrile, and methanol as the mobile phases, and a flow rate of 0.6 ml/min.
Statistical Analysis
Data are reported as mean AE SEM values. The statistics software program Prism (GraphPad Software, Inc., La Jolla, CA) was used to perform 1-way or 2-way repeated measures analysis of variance (ANOVA), Bonferroni post hoc tests, and Student's t-tests.
RESULTS
Apremilast Reduces Voluntary EtOH Consumption in the 2BC Test
In the continuous 2BC test, single injections of apremilast dose dependently reduced 15% EtOH intake [F(4, 31) = 12.2, p < 0.001], preference for EtOH [F(4, 31) = 5.2, p < 0.01], and total fluid intake [F(4, 31) = 6.1, p < 0.01] in C57BL/6J male mice (Fig. 1A-C) . The data shown represent the differences between 2-day drinking averages after drug injection (days 3, 4 after apremilast) and the first 2 days of saline (control) injections (days 1, 2). Two-day averages account for the effects of different bottle positions on drinking behavior and provide a more accurate measurement of EtOH intake and drug effects. The raw drinking data in male mice are shown in Fig. S1A -C. Post hoc analyses showed significant decreases in all drinking parameters at doses of 30 to 50 mg/kg, while 15 mg/kg of apremilast reduced the amount of EtOH consumed without changing total fluid intake. There was a trend for 15 mg/kg to reduce preference for EtOH, but this did not reach statistical significance. In female mice, apremilast also dose dependently reduced EtOH intake [F(4, 27) = 15.8, p < 0.001], preference for EtOH [F(4, 27) = 9.4, p < 0.001], and total fluid intake [F (4, 27) = 15.5, p < 0.001; Fig. 1D-F] . The raw drinking data in female mice are shown in Fig. S1D-F . Post hoc analyses showed that 15 to 50 mg/kg apremilast significantly decreased the amount of EtOH consumed and preference for EtOH, and 30 to 50 mg/kg apremilast also reduced total fluid intake. The lowest dose of apremilast tested (5 mg/kg) did not significantly alter EtOH consumption in male or female mice. Based on the dose-response effects, a 20 mg/kg dose was chosen for chronic drug treatment experiments.
Six daily injections of apremilast (20 mg/kg) significantly reduced EtOH consumption [F(1, 14) = 12.8, p < 0.001, effect of treatment; F(2, 28) = 3.8, p < 0.05, effect of time] and Fig. 3 . Apremilast dose dependently decreases 15% ethanol (EtOH) intake in the 2BC-EOD test. Effects of apremilast (5 to 50 mg/kg) on EtOH intake (A), preference for EtOH (B), and total fluid intake (C) in male C57BL/6J mice; n = 8 per group. Effects of apremilast (5 to 50 mg/kg) on EtOH intake (D), preference for EtOH (E), and total fluid intake (F) in female C57BL/6J mice; n = 11 per group. Data are presented as the differences between 2-day drinking averages after drug injection (days 3, 4 after apremilast) and the first 2 days of saline (control) injections (days 1, 2). Data were analyzed by 1-way ANOVA with Bonferroni post hoc tests (*p < 0.05, **p < 0.01, ***p < 0.001 compared with control).
preference for EtOH [F(1, 14) = 9.9, p < 0.001, effect of treatment], but did not alter total fluid consumption in male mice ( Fig. 2A-C) . During the washout phase when injection of apremilast was replaced with saline, mice previously treated with apremilast showed no differences in EtOH consumption or preference compared with control mice. Similar to male mice, 6 daily injections of apremilast (20 mg/kg) in female mice reduced EtOH consumption [F(1, 16) = 16.4, p < 0.001, effect of treatment] and preference for EtOH [F(1, 16) = 4.6, p < 0.05, effect of treatment; F(2, 32) = 4.4, p < 0.05, effect of time], but did not change total fluid consumption (Fig. 2D-F) . During the washout phase, female mice previously treated with apremilast showed no differences in EtOH intake or preference compared with control mice.
Apremilast Reduces Voluntary EtOH Consumption in the 2BC Intermittent Drinking Test
Compared with 2BC continuous drinking, intermittent access usually produces higher EtOH intake in mice and can be used to model a different pattern of drinking in humans. In the 2BC-EOD test, single injections of apremilast dose dependently reduced 15% EtOH intake, F(4, 35) = 8.2, p < 0.001, and total fluid intake, F(4, 35) = 4.5, p < 0.01, but did not alter preference for EtOH in C57BL/6J male mice (Fig. 3A-C) . Figure 3 shows the differences between 2-day drinking averages after drug injection (days 3, 4 after apremilast) and the first 2 days of saline (control) injections (days 1, 2). The raw drinking data in male mice are shown in Fig. S2A-C . Post hoc analyses showed that all doses of apremilast significantly reduced the amount of EtOH consumed. Apremilast (30 to 50 mg/kg) reduced total fluid intake, and 50 mg/kg decreased preference for EtOH. In female mice, apremilast dose dependently reduced EtOH intake [F(4, 50) = 7.3, p < 0.001], preference for EtOH [F(4, 50) = 6.2, p < 0.001], and total fluid intake [F(4, 50) = 3.3, p < 0.05; Fig. 3D-F] . The raw drinking data in female mice are shown in Fig. S2D-F . Post hoc analyses revealed significant reductions in EtOH intake and preference by 30 to 50 mg/kg of apremilast, and only the 50 mg/kg dose significantly reduced total fluid intake.
In the 2BC-EOD test, 11 daily injections of apremilast (20 mg/kg, administered on the 6 drinking days and on Fig. 4 . Apremilast produces stable reduction of 15% ethanol (EtOH) intake in the 2BC-EOD test. Effects of apremilast (20 mg/kg) on EtOH intake (A), preference for EtOH (B), and total fluid intake (C) in male C57BL/6J mice; n = 10 per group. Effects of apremilast (20 mg/kg) on EtOH intake (D), preference for EtOH (E), and total fluid intake (F) in female C57BL/6J mice; n = 10 per group. Each data point represents the average of 2 days of drinking. S/S represents 2-day drinking averages after saline injections for both groups. S/Drug represents the 2-day averages after saline or apremilast injections (11 days total). The second S/S period shows the extinction of effects on drinking in mice previously treated with apremilast. Data were analyzed by 2-way repeated measures ANOVA with Bonferroni post hoc tests (**p < 0.01 compared with corresponding control time point).
intervening days) reduced the amount of EtOH consumed [F (1, 360) = 89.1, p < 0.001, effect of treatment; F(2, 36) = 4.6, p < 0.05, effect of time], preference for EtOH [F(1, 36) = 28.4, p < 0.001, effect of treatment], and total fluid intake [F(1, 36) = 5.2, p < 0.05, effect of treatment; F(2, 36) = 7.1, p < 0.05, treatment 9 time interaction] in male mice (Fig. 4A-C) . During the washout phase, mice previously treated with apremilast showed no differences from control mice. In female mice, 11 daily injections of apremilast (20 mg/kg) significantly reduced EtOH intake [F(1, 18) = 4.6, p < 0.05, effect of treatment], but did not alter preference for EtOH or total fluid intake ( Fig. 4D-F) .
Effects of Apremilast on Saccharin, Sucrose, and Water Consumption
In the 2BC test (continuous 24-hour access to saccharin and water) in male mice, apremilast (20 mg/kg) did not alter preference for saccharin or total fluid (saccharin plus water) intake (Fig. 5A,B ). There was no treatment effect on water intake measured in a separate experiment (Fig. 5C) . Apremilast also did not change preference for saccharin or total fluid intake in female mice (Fig. 5D,E) . There was a time 9 treatment interaction effect on water intake, F(5, 50) = 3.8, p < 0.01 (Fig. 5F) ; post hoc analysis showed that apremilast treatment significantly reduced water intake in female mice only during the first 2 days of treatment.
There was also no effect of apremilast on preference for sucrose or total fluid intake in male (Fig. 6A,B) or female (Fig. 6C,D) mice.
Locomotor Activity
We studied the acute effect of apremilast (20 mg/kg) on spontaneous locomotor activity measured hourly for 22 hours (Fig. 7) . The main effect of apremilast treatment was not significant in male mice, but there was a significant time 9 treatment interaction, F(21, 630) = 1.7, p < 0.05 (Fig. 7A) , although post hoc tests did not show significant differences at any time point. In contrast to male mice, an Fig. 5 . Apremilast does not alter preference for saccharin or water intake. Effects of apremilast (20 mg/kg) on preference for saccharin (A), total fluid intake (B), and water intake (C) in male C57BL/6J mice; n = 6 per group for the saccharin experiment and n = 5 to 6 per group for the water experiment. Effects of apremilast (20 mg/kg) on preference for saccharin (D), total fluid intake (E), and water intake (F) in female C57BL/6J mice; n = 6 per group. For 2BC saccharin drinking, data points represent the average of 2 days of drinking. For water intake using 1 bottle of water, data are presented as daily intake. S/S represents 2 days of saline injections for both groups. S/Drug represents saline or apremilast injections (6 days total for the saccharin experiment and 8 days total for the water experiment). Data were analyzed by 2-way repeated measures ANOVA with Bonferroni post hoc tests (*p < 0.05 compared with corresponding control time point).
overall reduction in motor activity was observed in females treated with apremilast [F(1, 30) = 10.7, p < 0.01, effect of treatment; F(21, 630) = 50.5, p < 0.001, effect of time; F(21, 630] = 3.2, p < 0.001, time 9 treatment interaction; Fig. 7C ]. The apremilast effect on motor activity was also evaluated by comparing the areas under the motor activity curves, which showed a reduction in motor activity in female (p < 0.01) but not in male mice (Fig. 7B,D) .
We also measured locomotor activity in male and female mice after repeated (6 daily injections) administration of apremilast (20 mg/kg) because we had used repeated dosing in our drinking studies. Motor activity was significantly reduced in males [F(1, 30) = 8.5, p < 0.01, effect of treatment; F(21, 630) = 41.4, p < 0.001, effect of time; F(21, 630] = 3.5, p < 0.001, time 9 treatment interaction; Fig. 8A ] but not in females (Fig. 8C) . There was also significant reduction in the area under the curve in male (p < 0.01) but not in female mice after repeated injections (Fig. 8B,D) .
Blood EtOH Clearance
Pretreatment with apremilast did not affect blood EtOH clearance in male or female mice (Fig. 9A,B) . Comparison of the slopes of the regression lines showed no effect of apremilast in male (À68 AE 3 for saline and À71 AE 3 for apremilast pretreatment) or female mice (À52 AE 3 for saline and À49 AE 3 for apremilast pretreatment).
Biodistribution of Apremilast
Maximum plasma levels in mice and humans were found 2 hours after a single oral dose of apremilast (https://www. tga.gov.au/sites/default/files/auspar-apremilast-151022.pdf). We thus collected plasma, liver, and brain samples from male mice 1 or 2 hours after a single treatment with apremilast (20 mg/kg). The highest levels of apremilast were found in liver followed by plasma and brain (Table 1) . Fig. 6 . Apremilast does not alter preference for sucrose. Effects of apremilast (20 mg/kg) on preference for sucrose (A) and total fluid intake (B) in male C57BL/6J mice; n = 6 per group. Effects of apremilast (20 mg/kg) on preference for sucrose (A) and total fluid intake (B) in female C57BL/6J mice; n = 6 per group. Data are presented as 2-day drinking averages. S/S represents 2 days of saline injections for both groups. S/Drug represents saline or apremilast injections (8 days total). Data were analyzed by 2-way repeated measures ANOVA with Bonferroni post hoc tests, but no significant group differences were found.
DISCUSSION
The PDE4 inhibitor rolipram decreased EtOH intake and preference in mice (Blednov et al., 2014; Hu et al., 2011) , as well as EtOH seeking and consumption in rats (Wen et al., 2012) . In this study, we showed that apremilast, another selective inhibitor of PDE4, also reduced EtOH intake and preference in the 2BC and 2BC-EOD tests. Unlike rolipram, which transiently reduced EtOH drinking, apremilast produced long-lasting decreases. Apremilast was effective within a similar range of doses in male and female mice, but its overall effectiveness in reducing EtOH intake was greater in male compared with female mice. Only the higher doses (30 to 50 mg/kg) reduced total fluid intake. This effect may have been due to the sedative action of PDE4 inhibitors (Hu et al., 2011) . Although 20 mg/kg of apremilast reduced spontaneous locomotor activity, this was not likely a factor in reducing EtOH consumption because this dose did not affect total fluid consumption. In rodents, there is a positive correlation between EtOH intake and consumption of sweet solutions, as shown in studies of inbred strains, hybrid mice, and taste-deficient mutants (Bachmanov et al., 1996; Blednov et al., 2008; Yoneyama et al., 2008) . However, apremilast did not alter consumption of a sweet solution of saccharin or a sweet and highly caloric solution of sucrose.
Despite being introduced in the late 1980s, the clinical use of PDE inhibitors has been hampered because of lack of efficacy and gastrointestinal side effects such as nausea and vomiting (Giembycz, 2008) . One approach to mitigating these adverse effects is to seek agents with selectivity for PDE4 isoforms not associated with toxic effects. PDE4 isozymes are encoded by 4 genes (A, B, C, and D), and inhibition of PDE4D is thought to promote emesis (Robichaud et al., 2002) , whereas selective inhibition of PDE4A or PDE4B in proinflammatory and immune cells is thought to produce the desired anti-inflammatory effects (Giembycz, Fig. 7 . Acute administration of apremilast (20 mg/kg) decreases locomotor activity in female mice. Spontaneous locomotion recorded every hour (A) and area under the curve (B) in male C57BL/6J mice (n = 16 per group). Spontaneous locomotion (C) and area under the curve (D) in female C57BL/6J mice (n = 16 per group). Spontaneous locomotor data were analyzed by 2-way repeated measures ANOVA with Bonferroni post hoc tests (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with corresponding control time point). Area under the curve data were analyzed using Student's ttests (**p < 0.01 compared with saline control).
2008; Jin et al., 2012) . Apremilast is a partial competitive inhibitor of PDE4 but does not demonstrate marked PDE4 subfamily (A to D) selectivity . In comparison, cilomilast is 10-fold more selective for PDE4D (Giembycz, 2001) , the isozyme associated with emesis. The lack of PDE4D selectivity of apremilast may in part explain its improved therapeutic index compared with cilomilast in preclinical models (see Schett et al., 2010) .
The anti-inflammatory effects of PDE4 inhibitors may be important in their ability to decrease EtOH drinking. Lipopolysaccharide (LPS), proinflammatory cytokines, and EtOH all increase the activity of PDE4 in several cell types (microglia, astrocytes, bronchial epithelial), and rolipram reversed these effects (Buttini et al., 1997; Forget et al., 2003; Ghosh et al., 2012) . Rolipram dose dependently decreased LPS-induced production of tumor necrosis factor (TNF)-a in rat brain and microglia (Buttini et al., 1997; Yoshikawa et al., 1999) . Apremilast is also known to regulate immune signaling. For example, it inhibited production of TNF-a (Man et al., 2009) , interferon (INF)-a, and cytokines (Schafer et al., 2014) . Overall, the pharmacological effects of apremilast are consistent with those of a selective PDE4 inhibitor with fewer side effects that also inhibits innate immune responses. Considering the accumulating evidence for immune/inflammatory mechanisms in AUD , apremilast may decrease drinking by targeting these peripheral and central neuroimmune pathways. One approach to test this mechanism would be to determine whether apremilast inhibits changes in neuroimmune gene expression induced by EtOH (McCarthy et al., 2017; Osterndorff-Kahanek et al., 2013) . To determine whether the effects of apremilast are related to decreased production of TNF-a or INF-a, another approach would be to compare its effects on drinking with a more specific antagonist for these receptors.
In mice and humans, the time to reach maximum plasma concentrations after a single oral dose of apremilast was similar (~2 hours; https://www.tga.gov.au/sites/default/files/ auspar-apremilast-151022.pdf), suggesting rapid absorption; thus, the 1-and 2-hour time points that we measured should Fig. 8 . Chronic administration of apremilast (20 mg/kg) decreases locomotor activity in male mice. Apremilast was given daily for 6 days. Spontaneous locomotion recorded every hour (A) and area under the curve (B) in male C57BL/6J mice (n = 16 per group). Spontaneous locomotion (C) and area under the curve (D) in female C57BL/6J mice (n = 16 per group). Spontaneous locomotor data were analyzed by 2-way repeated measures ANOVA with Bonferroni post hoc tests (*p < 0.05, **p < 0.01, ****p < 0.0001 compared with corresponding control time point). Area under the curve data were analyzed using Student's t-tests (**p < 0.01 compared with saline control).
represent near peak plasma levels. It is of interest to compare the concentrations of apremilast found in our study with those needed to produce anti-inflammatory actions. The plasma level of 2.1 ng/ll (Table 1) corresponds to 4.6 lM of total drug. However, free drug concentrations are more reflective of activity (Muller and Milton, 2012) , and apremilast is 89% bound in mouse plasma (http://www.ema.eu ropa.eu/docs/en_GB/document_library/EPAR_-_Public_a ssessment_report/human/003746/WC500182629.pdf), giving a free concentration of 0.5 lM. The concentrations required to inhibit cytokine production are similar or lower (IC 50 values in lM: INF-c, 0.013; TNF-a, 0.11; MCP-1, 1.3; Schafer et al., 2010) . Although brain levels of apremilast were much lower than those detected in plasma and liver, the drug did reach the brain 1 to 2 hours after a single oral treatment at levels similar to the calculated free concentration in plasma. This evidence, along with the effects on EtOH drinking that we observed after systemic treatment, indicate that apremilast can act centrally, further supporting the feasibility of using PDE4 inhibitors to treat CNS diseases. In this regard, it is interesting to compare clinical concentrations with those in our study. Human doses of 100 mg/d (roughly equivalent to the mouse doses of 20 mg/kg used in our study; Nair and Jacob, 2016) resulted in peak total plasma levels of 0.99 ng/ ll (https://www.accessdata.fda.gov/drugsatfda_docs/nda/ 2014/205437Orig1s000ClinPharmR.pdf). The drug is 68% bound in human plasma (http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Public_assessment_re port/human/003746/WC500182629.pdf), resulting in a free drug concentration of 0.7 lM. This is somewhat higher than found in mice, again supporting the feasibility of clinical testing of apremilast to treat AUD.
As discussed above, we and others showed that PDE4 inhibitors such as rolipram reduce voluntary EtOH consumption in different rodent models. Rolipram was initially developed as an antidepressant but gastrointestinal side effects caused clinical use to be discontinued. Our current findings suggest that apremilast may be a more promising PDE4 inhibitor for clinical testing and repurposing to treat AUD. Our companion article examines the effects of apremilast on other EtOH-related behaviors that can impact EtOH consumption (Blednov et al., 2018) . Subtype-selective inhibitors targeting PDE4B are of interest given the role for PDE4B in immune function versus the association of PDE4D with nausea and vomiting. In addition to its function in immune signaling, PDE4B may be of particular interest in AUD because it is localized in brain reward pathways (Cherry and Davis, 1999) , its expression is up-regulated in mice with a genetic predisposition for high EtOH consumption (Mulligan et al., 2006) , and a large genome-wide association study linked PDE4B with EtOH consumption in humans (Clarke et al., 2017) . In addition, Pde4b expression is critical for EtOH-induced neuroinflammatory responses (Avila et al., 2015 (Avila et al., , 2017 . Continued drug discovery efforts to identify well-tolerated PDE4 inhibitors with improved ability to reach the brain may help advance the treatment outlook for many inflammatory and immune-related CNS disorders.
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